In prostate cancer, the PROfound trial showed olaparib significantly improves outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA1/2 and ATM pathogenic variants compared to hormone therapy [13], while TRITON3 highlighted rucaparib’s effectiveness in delaying disease progression for those with BRCA1/2 pathogenic variants [14]. The gene discussed is BRCA1; the disease is Familial prostate cancer.